Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
Source: The ASCO Post, November 2024
In a pooled analysis of long-term outcomes reported in the Journal of Clinical Oncology, Long et al found that nivolumab plus ipilimumab was associated with better overall survival vs nivolumab monotherapy in immune checkpoint inhibitor treatment–naive patients with unresectable or metastatic melanoma.
Study Details
The study involved pooled long-term data from six CheckMate studies in immune checkpoint inhibitor treatment–naive patients receiving nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg; nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg; or nivolumab monotherapy at 3 mg/kg. The primary outcome measure for the analysis was overall survival.
Key Findings
Median follow-up for overall survival was 45.0 months among 839 patients receiving nivolumab plus ipilimumab and 35.8 months among 536 receiving nivolumab monotherapy.